Press-release for stocks related to trial

Prices are updated after-hours

Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors
Published: 2022-05-10 (Crawled : 12:00) - immatics.com
IMTX | $10.15 -2.59% -2.66% 220K

| 39.87% | O: -8.46% H: 11.95% C: 0.73%
ima401 trial phase 1

| -17.04% | O: 0.08% H: 2.07% C: -13.92%
ongoing phase 1 trial ima203 solid tumors response phase 1b

62%

38%

CSSE 4 | $0.4323 183.85% 64.77% 220M

BOF | $1.99 70.09% 41.21% 110M

ILAG | $0.51 6.03% 40.62% 1.7M

LICN | $0.941 68.04% 40.49% 15M

AMST | $3.31 65.5% 39.58% 70M

MTC | $3.615 61.38% 38.04% 9.3M

WIMI | $1.15 58.53% 36.92% 19M

AIH | $0.45 12.5% 30.92% 320K

MULN | News | $3.78 38.46% 27.78% 13M

RILY | $29.86 37.48% 27.26% 12M

Save your searches and get alerts when important news are released.